Lucid Diagnostics LUCD 深 滬
等待開盤 11-04 09:30:00 美东时间
0.409
+0.003
+0.66%
華盛通- 最 高0.4343
- 今 開0.40
- 成交量 161.41万股
- 最 低 0.396
- 昨 收 0.4063
- 總市值 7.81万
- 52周最高 1.6293
- 市盈率 靜 --
- 換手率 0.85%
- 52周最低 0.303
- 委 比 -86.82%
- 總股本 0.00亿
- 歷史最高 13.52
- 量 比 0.33
- 振 幅 9.43%
- 歷史最低 0.303
- 每 手 1
- 風險率 0.23%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多PAVmed Unit Lucid Diagnostics Announces Publication Of Clinical Findings From Nonendoscopic Esophageal Precancer Testing Using The EsoGuard; Study Demonstrates Efficiency And Scalability Of EsoCheckCell Collection In Under Two Minutes
The manuscript, "Non-Endoscopic Screening for Barrett's Esophagus Using a DNA Methylation-Based Assay: Real-World Experience in 11,991 Patients," published in the journal Diagnostics, reported that EsoCheck cell collection was rapid, well tolerated, and consistent across operators, including newly t...
11-03 21:17
Lucid Diagnostics Announces Publication of Landmark 12,000-Patient Real-World EsoGuard® Study
Largest peer-reviewed study of nonendoscopic esophageal precancer testing to date demonstrates the efficiency and scalability of EsoCheck® cell collection in under two minutes NEW YORK, Nov....
11-03 21:15
PAVmed Inc.收跌2.05%，成交额1.23万美元
11月3日，PAVmed Inc.（PAVM）收跌2.05%，报1.91美元，成交额1.23万美元，市值1527.22万美元。 行情数据 • 开盘价：1.89美...
11-03 08:51
PAVmed Inc.收涨4.15%，成交额9904美元
10月27日，PAVmed Inc.（PAVM）收涨4.15%，报2.26美元，成交额9904美元，市值1807.07万美元。 行情数据 • 开盘价：2.22美...
10-27 07:49
美股大行评级 | 潜在涨幅94.37%！摩根士丹利上调西部数据(WDC)目标价至668美元，维持"超配"评级
今日重点评级关注：摩根士丹利：维持西部数据"超配"评级，目标价从643美元升至668美元；摩根大通：维持西部数据"超配"评级，目标价从600美元升至650美元
10-26 12:30
Lucid Diagnostics shares are trading higher after the company announced that begun receiving Medicare reimbursement payments for its EsoGuard Esophageal DNA Test.
Lucid Diagnostics shares are trading higher after the company announced that begun receiving Medicare reimbursement payments for its EsoGuard Esophageal DNA Test.
10-23 04:39
PAVmed Inc.收跌0.62%，成交额3.09万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 07:52
Lucid Diagnostics advances Medicare reimbursement and coding infrastructure
Lucid Diagnostics ( ($LUCD) ) has provided an update. On September 22, 2026, Lu...
09-22 21:29
Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways
Medicare Advisory Panel recommends maintaining EsoGuard's original gapfill payment basis under the Clinical Laboratory Fee Schedule AMA CPT Editorial Panel approves a new Category III CPT co...
09-22 19:55
美股大行评级 | 潜在涨幅1024.26%！Ascendiant Capital上调PAVmed目标价至57美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持PAVmed"买入"评级，目标价从56美元升至57美元；Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从9.25美元升至9.5美元
08-28 16:15
